Abstract：
OBJECTIVE: To quantify and compare the severity of metamorphopsia in patients undergoing vitrectomy for vitreoretinal disorders.
METHODS: Data were collected evaluated from 319 patients with vitreoretinal disorders, including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch retinal vein occlusion (BRVO-CME), CME with central retinal vein occlusion (CRVO), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD). Metamorphopsia was recorded with the M-CHARTS preoperatively and at 3 and 6 months postoperatively.
RESULTS: Preoperative and 6-month postoperative metamorphopsia scores were 0.69 ± 0.50 and 0.50 ± 0.52, respectively. Before surgery, 94% of patients presented with metamorphopsia (score ≥0.2). Preoperative metamorphopsia scores were significantly correlated with postoperative metamorphopsia scores (r = 0.378, p < 0.0001). Preoperative metamorphopsia score was significantly higher for ERM (0.89) than for DME (0.51). Vitrectomy significantly improved metamorphopsia in ERM and MH but not in the other disorders. In contrast, treatment improved visual acuity for all disorders except CRVO-CME and M-on RD.
CONCLUSIONS: This quantitative study indicated that metamorphopsia is present in most patients undergoing surgery for vitreoretinal diseases and is most severe in ERM. In these patients, vitrectomy improved visual acuity but not metamorphopsia.
METHODS: Data were collected evaluated from 319 patients with vitreoretinal disorders, including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch retinal vein occlusion (BRVO-CME), CME with central retinal vein occlusion (CRVO), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD). Metamorphopsia was recorded with the M-CHARTS preoperatively and at 3 and 6 months postoperatively.
RESULTS: Preoperative and 6-month postoperative metamorphopsia scores were 0.69 ± 0.50 and 0.50 ± 0.52, respectively. Before surgery, 94% of patients presented with metamorphopsia (score ≥0.2). Preoperative metamorphopsia scores were significantly correlated with postoperative metamorphopsia scores (r = 0.378, p < 0.0001). Preoperative metamorphopsia score was significantly higher for ERM (0.89) than for DME (0.51). Vitrectomy significantly improved metamorphopsia in ERM and MH but not in the other disorders. In contrast, treatment improved visual acuity for all disorders except CRVO-CME and M-on RD.
CONCLUSIONS: This quantitative study indicated that metamorphopsia is present in most patients undergoing surgery for vitreoretinal diseases and is most severe in ERM. In these patients, vitrectomy improved visual acuity but not metamorphopsia.
摘要：
目的：量化和比较玻璃体视网膜疾病的玻璃体切除术患者的变形严重程度。
方法：收集了319例玻璃体视网膜疾病患者的数据，包括视网膜前膜（ERM），黄斑裂孔(MH),黄斑囊样水肿伴视网膜分支静脉阻塞（BRVO-CME），CME伴视网膜中央静脉阻塞（CRVO），糖尿病性黄斑水肿（DME），黄斑脱离型孔源性视网膜脱离（M-offRD），和黄斑上RD（M-onRD）。术前和术后3个月和6个月用M-CHARTS记录变形。
结果：术前和术后6个月的变形评分分别为0.69±0.50和0.50±0.52。手术前,94%的患者出现变形视（评分≥0.2）。术前变形评分与术后变形评分显著相关(r=0.378,p<0.0001)。ERM的术前变形评分（0.89）明显高于DME（0.51）。玻璃体切除术可显着改善ERM和MH的变形，但未改善其他疾病。相比之下,治疗改善了除CRVO-CME和M-onRD外的所有疾病的视力。
结论：这项定量研究表明，在大多数接受玻璃体视网膜疾病手术的患者中存在变形，并且在ERM中最为严重。在这些患者中,玻璃体切除术可改善视力，但未改善变形。
方法：收集了319例玻璃体视网膜疾病患者的数据，包括视网膜前膜（ERM），黄斑裂孔(MH),黄斑囊样水肿伴视网膜分支静脉阻塞（BRVO-CME），CME伴视网膜中央静脉阻塞（CRVO），糖尿病性黄斑水肿（DME），黄斑脱离型孔源性视网膜脱离（M-offRD），和黄斑上RD（M-onRD）。术前和术后3个月和6个月用M-CHARTS记录变形。
结果：术前和术后6个月的变形评分分别为0.69±0.50和0.50±0.52。手术前,94%的患者出现变形视（评分≥0.2）。术前变形评分与术后变形评分显著相关(r=0.378,p<0.0001)。ERM的术前变形评分（0.89）明显高于DME（0.51）。玻璃体切除术可显着改善ERM和MH的变形，但未改善其他疾病。相比之下,治疗改善了除CRVO-CME和M-onRD外的所有疾病的视力。
结论：这项定量研究表明，在大多数接受玻璃体视网膜疾病手术的患者中存在变形，并且在ERM中最为严重。在这些患者中,玻璃体切除术可改善视力，但未改善变形。
